A Phase III Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 [casopitant] for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis.

Trial Profile

A Phase III Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 [casopitant] for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Casopitant (Primary) ; Ondansetron (Primary)
  • Indications Postoperative nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2008 Actual start date changed from Dec 2005 to Mar 2006 as reported by Clinicaltrials.gov
    • 12 Oct 2008 Actual start date changed from Apr 2006 to Dec 2005 as reported by Clinicaltrials.gov
    • 19 Jul 2007 Status changed from recruiting to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top